Aviga Health · Strategic Advisory
Venture-grade rigor and hands-on clinical experience — for the companies shaping what medical devices become next.
15+
Years in Medtech
225+
Investigative Stories
2,000+
Expert Interviews
3
Top-Tier VC Firms
Our Philosophy
Most advisory firms speak the language of either finance or medicine. Aviga Health speaks both. We are a boutique firm built for the convergence of AI, medical device development, and the capital markets funding its growth.
From first-in-human studies to Series B, we work with founding teams, corporate strategics, and institutional investors to sharpen strategy, reduce risk, and move faster toward the moments that matter.
Equal comfort at the investor table and the operator's bench — from term sheets to trial protocols.
A practitioner's understanding of where AI creates durable value in regulated devices — and where it doesn't.
No junior analysts. No templated frameworks. Every engagement is led by a principal who has done this work themselves.
What We Do
End-to-end advisory across the Medtech value chain — from concept to clinical to capital.
Defining the right product for the right market, then building the clinical evidence that commands approval and adoption.
Diligence that reads between the lines of any pitch — interrogating clinical feasibility, regulatory pathways, and the real competitive landscape.
The message underneath the strategy — shaping how investors, partners, and the market understand what you're building.
Clients
Venture and private equity firms that need clinical insight alongside financial analysis — to separate genuinely defensible assets from well-packaged ones.
Corporate development teams evaluating AI-enabled acquisitions or building new capabilities in-house, where a misjudgment costs years, not just capital.
Early-stage teams who need a trusted partner who has navigated the full arc from prototype to FDA clearance — and knows what investors will ask before they ask it.
Reach out to discuss your next engagement.
Schedule a Consultation
Viral Gandhi has been on both sides of the Medtech table: as an investor at three top-tier institutions, and as a founder running his own clinical trials. That combination is uncommon. The perspective it produces is what Aviga is built around.
Most recently Principal at KCK Medtech, following investment roles at Longitude Capital, OrbiMed, and the corporate venture arm of Edwards Lifesciences (NYSE: EW). As a two-time founder — GlucoLens and Aperture Medical — he has lived both the pitch and the build.
Viral has run clinical programs from first-in-human studies through large-scale randomized trials. He served as VP of Clinical at Revamp Medical and led trial operations for the PARTNER trials at Edwards Lifesciences. His advisory work includes Auris Health, Imperative Care, and Hawthorne Health.
Before investing or operating, Viral led Medtech investigative coverage for the Financial Times Group — publishing 225+ stories and interviewing more than 2,000 industry figures. The pattern recognition and network that built are things no MBA can replicate.
B.S. & M.S. in Bioengineering, University of Pennsylvania · Stanford Biodesign Fellow · Judge and mentor at global industry accelerators.